Glenmark Pharmaceuticals

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark Pharmaceuticals

Glenmark said that this was the second clinical study after the successful Favipiravir monotherapy trial earlier this year.

published on : 9th October 2020

Favipiravir: DCGI seeks clarification from Glenmark

The top drug regulator has also asked for an explanation on the "pricing" of the drug.

published on : 20th July 2020

Glenmark gets USFDA nod to market generic drug Chlorzoxazone for muscle pain

This marks company's first abbreviated new drug application (ANDA) approval out of its new North American manufacturing facility based in Monroe, North Carolina.

published on : 27th May 2020

Glenmark Pharmaceuticals to study efficacy of two antiviral drugs for treating COVID-19

The Glenmark study will examine whether early administration of a combination of Favipiravir and Umifenovir enhances antiviral efficacy.

published on : 26th May 2020

Glenmark Pharma gets DCGI nod for clinical trials of Favipiravir antiviral tablets on COVID-19 patients

Favipiravir has demonstrated activity against influenza viruses and has been approved in Japan for the treatment of novel influenza virus infections, it added.

published on : 30th April 2020
IPL_2020